Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee
March 4, 2003
Consultants (Voting)
Victor Santana, M.D., St. Jude Children’s Hospital
Alice Ettinger, R.N., Association of Pediatric Oncology Nurses
Jerry Finklestein, M.D., University of California, Los Angeles
Patrick C Reynolds, M.D., Los Angeles Children’s Hospital
James Boyett, Ph.D., St. Jude Children’s Hospital
Henry Friedman, M.D., Duke University
Susan Cohn, M.D., Northwestern University
Nancy Keene, Independent advocate (patient rep.)
Susan Weiner, Ph.D., Children’s Cause (patient rep.)
Oncologic Drugs Advisory Committee Members
Jody Pelusi, F.N.P., Ph.D., North Arizona Hematology & Oncology Associates
Gregory Reaman, M.D., Children’s Hospital National Medical Center, Washington, D.C.
Guest Speakers (Non-Voting)
Malcolm Smith, M.D., Cancer Treatment & Evaluation Program, National Cancer Institute, NIH
International Guests (Non-Voting)
Francesco Pignatti, M.D., European Medicinal Evaluation Agency (EMEA)
Katherine Cheng, M.D., Medicines Control Agency, UK
Anne Mathieu-Boue, M.D., Agence Francaise de Securite Sanitaires de Produits de Sante (AFSSAPS)
Gilles Vassal, M.D., AFSSAPS, Institut Gustave Roussy, France
Harald Schweim, M.D., Bundes Institut fur Arzneimittel und Medizinprodukte (Bfarm)
Mark Bernstein, M.D., Health Protection Branch, Canada
Industry Guests (Non-Voting)
Anne Hagey, M.D., Abbott Laboratories Global Oncology Development Group
Alan Melemed, M.D., Eli Lilly